Ignite Creation Date:
2024-05-06 @ 7:46 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06129890
Status:
RECRUITING
Last Update Posted:
2024-04-30
First Post:
2023-10-24
Brief Title:
Neuromodulation in Patients With Neuropathic Pain and Depression
Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Organization:
Centre Hospitalier Universitaire de Saint Etienne
Study Overview
Official Title:
Neuromodulation in Patients With Neuropathic Pain and Depression a Cross-over Study Between Two Targets in Transcranial Magnetic Stimulation the Primary Motor Cortex and the Dorsolateral Prefrontal Cortex
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DOLODEP
Brief Summary:
High-frequency repetitive transcranial magnetic stimulation of the primary motor cortex has shown its effect on refractory neuropathic pain and rTMS of the dorsolateral prefrontal cortex is commonly used for treatment-resistant depression
The treatment for patients suffering from neuropathic pain and depression concomitantly still needs to be studied as there are some specificities in both symptoms and brain functional MRI
The treatment for patients suffering from neuropathic pain and depression concomitantly still needs to be studied as there are some specificities in both symptoms and brain functional MRI
Detailed Description:
This project is a cross-over study for these patients including 4 sessions of either M1 or DLPFC rTMS a wash-out period followed by 4 sessions of the other stimulation site to assess the efficiency of a DLPFC rTMS for neuropathic pain with a comorbid depression Besides pain intensity and quality patients mood quality of life and catastrophizing will be assessed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ANSM | OTHER | 2023-A01346-39 | None |